Abstract Body

Some payors include alcohol abstinence as a requirement for reimbursement of direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection. However, it remains unclear if alcohol use is associated with lower likelihood of sustained virologic response (SVR) to DAA therap. We examined the relationship between alcohol use, assessed within the 18 months prior to DAA therapy, and SVR.

Using the Veterans Health Administration (VA) Birth Cohort, which includes all Veterans born between 1945 and 1965, we identified HCV patients dispensed DAA therapy between 1 January 2014 and 31 December 2018. Alcohol use (abstinent, abstinent with history of alcohol use disorder [AUD], lower risk, moderate risk, high risk) was determined using a combination of self-reported score from the Alcohol Use Disorders Identification Test-Consumption instrument and validated International Classification of Diseases, 9th/10th Revision AUD diagnoses. We assessed SVR, defined as undetectable HCV RNA ?12 weeks after DAA therapy, through May 31, 2019. Multivariable logistic regression was used to determine odds ratios (ORs) with 95% confidence intervals (CIs) of SVR for each alcohol use category compared to lower risk, adjusting for HCV genotype, HBV coinfection, and hepatic decompensation. A stratified analysis was performed by HIV status.

Among 77,046 HCV patients dispensed DAA therapy (mean age, 63 years; 97% male; 50% white race; 83% HCV genotype 1; 3% HIV positive), alcohol use prior to DAA therapy varied: abstinent (47%), abstinent with AUD (13%) lower risk (19%), moderate risk (5%), and high risk (17%). Overall, 94% of patients achieved SVR. We observed no association with SVR among patients whose alcohol use was classified as abstinent (OR 1.06, 95% CI 0.96-1.16), abstinent with history of AUD (OR 0.91, 95% CI 0.81-1.03), moderate risk (OR 0.97, 95% CI 0.8-1.17), or high risk (OR 1.00, 95% CI 0.89-1.12) relative to lower risk alcohol use (Figure). Results were similar when stratified by HIV status; however, the HIV co-infected subset (n=2,372), was underpowered.

Level of alcohol use, even at the highest category of use, was not associated with a lower likelihood of achieving SVR after adjusting for important differences between the groups. These findings suggest that DAA therapy should be provided and reimbursed despite alcohol use. Restricting access to DAA therapy based on alcohol use is an unnecessary barrier to DAA therapy and challenges HCV elimination goals.